Patents by Inventor Andrew Souers

Andrew Souers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20160206611
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: January 13, 2016
    Publication date: July 21, 2016
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Methods of treatment using selective Bcl-2 inhibitors
    Patent number: 9345702
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • Tetracyclic CDK9 kinase inhibitors
    Patent number: 9328112
    Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 3, 2016
    Assignee: AbbVie Inc.
    Inventors: Robin Frey, Jane Gong, Zhiqin Ji, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
  • PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS
    Publication number: 20160060257
    Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: ABBVIE INC.
    Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iquturi, Madhu Babu Dabbeeru
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9266877
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: February 23, 2016
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20150299197
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • TETRACYCLIC CDK9 KINASE INHIBITORS
    Publication number: 20150218165
    Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Application
    Filed: December 12, 2014
    Publication date: August 6, 2015
    Applicant: ABBVIE INC.
    Inventors: Robin Frey, Jianchun Gong, Zhiqin JI, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20150150870
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.
    Type: Application
    Filed: November 6, 2014
    Publication date: June 4, 2015
    Inventors: Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20150152097
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 4, 2015
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 8940737
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 27, 2015
    Assignee: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 8889675
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 18, 2014
    Assignee: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20140275082
    Abstract: Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: February 10, 2014
    Publication date: September 18, 2014
    Inventors: Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
  • METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
    Publication number: 20120129853
    Abstract: This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.
    Type: Application
    Filed: November 22, 2011
    Publication date: May 24, 2012
    Applicant: Abbott Laboratories
    Inventors: Steven Elmore, Andrew Souers, Li Chun Wang, Tariq Ghayur, Stuart J. Perper
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Publication number: 20080064717
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R3, X, Q, Z, A, 9, m, and n are defined herein Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: May 17, 2007
    Publication date: March 13, 2008
    Inventors: Rajesh Iyengar, Gang Zhao, Jennifer Freeman, Ju Gao, Andrew Judd, Philip Kym, John Lynch, Mathew Mulhern, Andrew Souers
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050277638
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 15, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050209274
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 22, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187279
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: August 25, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187387
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 25, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137243
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Anil Vasudevan, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137187
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka